Medical Disorders in Pregnancy

Gestational Diabetes Mellitus

IN REVIEWv3🇮🇳 India-firstPENDING CLINICAL VERIFICATION

The India programme tests all pregnancies at the first ANC and repeats a negative early test at 24–28 weeks. Record the diagnostic framework: its non-fasting 75 g method differs from a fasting OGTT. Nutrition, monitoring and individualised medication follow diagnosis; plan birth and postpartum testing.

Admission & discharge ↓

Reviewer note: Medication regimens and dependent emergency instructions checked 17 October 2026. Named glucose-testing frameworks and identified diabetes dependencies checked 18 October 2026. These targeted checks do not certify every statement in the module. Admission/discharge guidance checked 18 October 2026. This adds a scoped clinical synthesis and does not certify every statement in the module.

Clinical detail

Additional detail checked 2026-10-17 against the linked sources. This check covers the section below; the rest of the module retains its displayed verification status.

Record which diagnostic framework is being used; thresholds from different gestational-diabetes guidelines are not interchangeable.

Assessment & interpretation

Discuss maternal and newborn implications of hyperglycaemia. Review the glucose pattern and teach self-monitoring rather than relying on a single isolated value.

Decisions that change management

Arrange diabetes–antenatal review and an individual plan for nutrition, activity and medicines when needed. Explain hypoglycaemia symptoms and what to do if unwell.

Follow-up & safety-netting

Document the locally adopted postnatal testing pathway before discharge and arrange ongoing surveillance for diabetes. Discuss weight, activity and planning another pregnancy.

Sources for this detail:

NICE · NG3checked

Admission & discharge

Care setting: Usually outpatient; admit acute metabolic or obstetric complications

Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.

When admission or continued hospital care is needed

Admit suspected DKA/ketosis with illness, severe/recurrent hypoglycaemia, dehydration, marked symptomatic hyperglycaemia or maternal/fetal compromise. Poor control may need supervised treatment adjustment.

When clinic, day care or home care may be suitable

Stable GDM is managed with education, glucose monitoring, nutrition and a reviewed medicine plan rather than automatic admission.

Before going home

The acute problem has resolved; the patient can eat/drink, monitor glucose and use any prescribed medicine safely, with supplies and a named reviewer.
After delivery, confirm whether this was GDM or pre-existing diabetes; persistent hyperglycaemia needs assessment.

Discharge medicines and treatment changes

Before birth, continue only the individually prescribed metformin/insulin plan and provide hypoglycaemia instructions.
NICE: stop GDM glucose-lowering therapy immediately after birth and reassess glucose before community transfer. Do not apply this stopping rule to type 1/type 2 diabetes.

Medicine doses — use only when indicated

Use the medicines selected for this patient. Listed alternatives are not instructions to prescribe all of them together. Confirm the actual remaining course, pregnancy/postnatal context and monitoring plan.

Antenatal use only if prescribed; GDM treatment is reassessed/stopped after birth under the documented plan.

Metformin immediate releaseMSFchecked

DoseWeek 1: 500 mg with breakfast; week 2: 500 mg twice daily; increase by 500 mg/week if tolerated and needed

RouteOral

FrequencyOnce daily initially, then twice daily with meals

DurationWhile indicated and tolerated; GDM treatment is normally stopped after birth, with a diabetes follow-up plan

Preparation500 mg tablets taken with meals. Use slower titration for gastrointestinal intolerance; do not silently substitute a modified-release product

Max dose2 g/day (1 g twice daily) for this MSF regimen

Indication: Selected GDM/type 2 diabetes; assess glucose, renal function and suitability for metformin versus insulin
Renal / hepatic: Avoid if eGFR <30; reduced dosing/closer review with moderate impairment; withhold during acute dehydration, hypoxia or renal deterioration
NICE NG3 permits metformin in selected pregnancies; placental transfer and treatment alternatives should be discussed.

Monitoring

Fasting and post-meal glucose; renal function before treatment and with acute illness; B12 with long-term use
Escalate to insulin when glucose targets are not reached or metformin is unsuitable

Contraindications: DKA, hypoxia, major dehydration or severe renal impairment

Antenatal individual insulin prescription, not a universal starting dose.

NPH (isophane) insulin with prescribed mealtime insulinMSFchecked

DosePatient-specific dose in UNITS; NPH once or twice daily, with separately prescribed meal doses if needed. A universal 0.3-units/kg starting prescription is not appropriate for every GDM pattern

RouteSubcutaneous only

FrequencyNPH once/twice daily; short-acting insulin before meals according to its formulation

DurationContinue and titrate throughout pregnancy; reduce/review promptly after birth. Type 1 diabetes always requires basal insulin

PreparationUse U-100 insulin with a matching insulin syringe/pen. Gently resuspend NPH until uniform. NPH is NEVER IV. If mixing compatible human insulins, draw clear short-acting insulin before cloudy NPH

Max doseNo universal fixed maximum: titrate the prescribed units against glucose and hypoglycaemia, with the diabetes team

Indication: Pregnancy diabetes: match basal and meal insulin to the glucose pattern
The linked NICE NG3 guidance provides pregnancy targets and treatment selection. The dose must be prescribed individually; this is an explicit dosing constraint, not a missing fixed dose.

Monitoring

Record the actual basal/meal doses in the patient plan; monitor fasting, premeal/postmeal glucose or CGM
Review patterns rather than a single high value; teach injection technique, recognition/treatment of hypoglycaemia and sick-day ketone testing
NICE targets, if achievable without problematic hypoglycaemia: fasting <5.3 mmol/L, 1-h postmeal <7.8 or 2-h <6.4; keep glucose >4 mmol/L on insulin

Contraindications: Current hypoglycaemia requires treatment and dose review; do not omit basal insulin in type 1 diabetes

Tests, pending results and their reviewer

Arrange postpartum diabetes testing, using one named pathway: India programme 75 g OGTT at 6 weeks; NICE fasting plasma glucose at 6–13 weeks, without routine postpartum OGTT. Use non-pregnant diagnostic interpretation.

Home care and counselling

Provide glucose/insulin supplies when indicated, nutrition/activity advice, feeding support and future-pregnancy testing/contraception advice.

Follow-up: when and what to review

When	Action / responsible service
Within 1 week of diagnosis (NICE)	Joint diabetes–antenatal review and an individual plan.
Before discharge after birth	Book the actual postpartum test and result review.
Annually after a negative postpartum test	Continue diabetes surveillance and seek preconception testing for a future pregnancy.

Return urgently

Vomiting/illness with hyperglycaemia or ketones, severe hypoglycaemia, inability to keep fluids down or reduced fetal movements requires urgent assessment.

Open the complete discharge checklist →

Sources for this plan:

NICE · NG3checked MoHFW / National Health Missionchecked MSFchecked MSFchecked

Treatment

① Immediate stabilization — first minutes

Acute presentations -> dka-pregnancy topic.

③ First-line treatment & drug regimens

Offer dietitian-supported nutrition, appropriate activity and glucose-monitoring education. Discuss medicine benefits, risks and preferences.
NICE: if fasting glucose is below 7.0 mmol/L at diagnosis, trial diet/activity; offer metformin if targets are not met in 1–2 weeks. Use insulin if metformin is unsuitable or targets remain unmet.
NICE: fasting glucose ≥7.0 mmol/L requires immediate insulin, with or without metformin. Consider immediate insulin at 6.0–6.9 mmol/L with macrosomia/hydramnios. Do not delay treatment of marked hyperglycaemia while awaiting a routine diet review.
The complete cards give the selected metformin regimen and the individualised NPH plan; there is no universal insulin starting dose for every pregnancy.

Metformin immediate releaseMSFchecked

DoseWeek 1: 500 mg with breakfast; week 2: 500 mg twice daily; increase by 500 mg/week if tolerated and needed

RouteOral

FrequencyOnce daily initially, then twice daily with meals

DurationWhile indicated and tolerated; GDM treatment is normally stopped after birth, with a diabetes follow-up plan

Preparation500 mg tablets taken with meals. Use slower titration for gastrointestinal intolerance; do not silently substitute a modified-release product

Max dose2 g/day (1 g twice daily) for this MSF regimen

Selected GDM/type 2 diabetes; assess glucose, renal function and suitability for metformin versus insulin
NICE NG3 permits metformin in selected pregnancies; placental transfer and treatment alternatives should be discussed.
Renal / hepatic: Avoid if eGFR <30; reduced dosing/closer review with moderate impairment; withhold during acute dehydration, hypoxia or renal deterioration

Monitoring

Fasting and post-meal glucose; renal function before treatment and with acute illness; B12 with long-term use
Escalate to insulin when glucose targets are not reached or metformin is unsuitable

Contraindications: DKA, hypoxia, major dehydration or severe renal impairment

NPH (isophane) insulin with prescribed mealtime insulinMSFchecked

DosePatient-specific dose in UNITS; NPH once or twice daily, with separately prescribed meal doses if needed. A universal 0.3-units/kg starting prescription is not appropriate for every GDM pattern

RouteSubcutaneous only

FrequencyNPH once/twice daily; short-acting insulin before meals according to its formulation

DurationContinue and titrate throughout pregnancy; reduce/review promptly after birth. Type 1 diabetes always requires basal insulin

Max doseNo universal fixed maximum: titrate the prescribed units against glucose and hypoglycaemia, with the diabetes team

Pregnancy diabetes: match basal and meal insulin to the glucose pattern
The linked NICE NG3 guidance provides pregnancy targets and treatment selection. The dose must be prescribed individually; this is an explicit dosing constraint, not a missing fixed dose.

Monitoring

Record the actual basal/meal doses in the patient plan; monitor fasting, premeal/postmeal glucose or CGM
Review patterns rather than a single high value; teach injection technique, recognition/treatment of hypoglycaemia and sick-day ketone testing
NICE targets, if achievable without problematic hypoglycaemia: fasting <5.3 mmol/L, 1-h postmeal <7.8 or 2-h <6.4; keep glucose >4 mmol/L on insulin

Contraindications: Current hypoglycaemia requires treatment and dose review; do not omit basal insulin in type 1 diabetes

Offer insulin when metformin is contraindicated, unacceptable or insufficient. Choose basal/prandial components from the measured glucose pattern with the diabetes team; teach injection technique and hypoglycaemia treatment.

Definitive treatment

Agree timing and mode of birth from glucose control, growth and maternal/fetal complications. India 2018 does not recommend routine birth before 39 weeks and schedules induction at or after 39 weeks when well controlled. NICE advises birth no later than 40+6 weeks for uncomplicated GDM, with earlier birth when complications warrant it. The comparison in Management principles explains the default; insulin use alone does not create a universal 38-week rule.

Monitoring

Domain	Schedule / action
Glucose monitoring	Record fasting and post-meal glucose with timing and targets; review promptly after diagnosis and treatment changes.
Growth / fluid	Follow the documented India or NICE ultrasound schedule; assess sooner for a clinical concern.
BP / proteinuria	Each routine face-to-face visit; symptoms or new hypertension require assessment.
Steroid courses / acute illness	Plan increased glucose monitoring and a written individual insulin adjustment; check ketones when unwell and assess urgently for suspected DKA.

Labour and postpartum glucose plan: NICE: monitor capillary glucose hourly during labour/birth and aim for 4–7 mmol/L (72–126 mg/dL). Use a prescribed IV insulin/dextrose plan when targets cannot be maintained; the infusion rate must follow the glucose response, not a fixed universal insulin-to-glucose ratio. India 2018 describes a different two-hourly labour schedule; the comparison below explains the selected default. After birth, stop GDM glucose-lowering treatment with glucose reassessment and a documented plan if hyperglycaemia persists; do not apply this stopping rule to pre-existing diabetes.

Response assessment

Targets met without severe hypoglycaemia
Normal growth trajectory

Treatment failure

Postprandial excursions -> intensify prandial insulin
Dawn phenomenon -> adjust basal

Second-line treatment

Basal-bolus intensification; CGM for problem patterns

Rescue treatment

Severe hypoglycaemia: call for help, assess airway and check glucose promptly. Do not give oral treatment to an unconscious patient. Use the complete IV glucose card; glucagon is an alternative when IV access is unavailable. Recheck glucose and treat the cause after recovery.

Glucose — severe hypoglycaemiaJBDS-IP / ABCD / Diabetes UKchecked

Dose20 g glucose: 200 mL of 10% OR 100 mL of 20% solution

RouteIV infusion

FrequencyGive over 10–15 min; recheck glucose at 10 min and repeat if still <4 mmol/L with reassessment

DurationAcute rescue followed by longer-acting carbohydrate when awake and safe to swallow, or prescribed ongoing infusion

Preparation10% =100 mg/mL; 200 mL =20 g. 20% =200 mg/mL; 100 mL =20 g. Check IV patency and use a limited volume so a whole large bag cannot infuse accidentally

Max doseReassess after each 20 g treatment; recurrent/prolonged hypoglycaemia needs monitored ongoing treatment

Impaired consciousness or unsafe swallowing; never give oral fluid to an unconscious patient

Monitoring

Glucose 10 min after treatment, then serially until stable; consciousness, swallow and IV site
Identify missed food, insulin excess, renal failure or infection; do not omit basal insulin in type 1 diabetes

Contraindications: Do not give oral sugar when swallowing is unsafe; hypertonic glucose extravasation can injure tissue

GlucagonJBDS-IP / ABCD / Diabetes UKchecked

Dose1 mg

RouteIM

FrequencyOne rescue dose; obtain IV access and recheck glucose after 10 min

DurationBridge to reliable glucose delivery; give carbohydrate after recovery

PreparationReconstitute the 1 mg vial with its supplied solvent immediately before IM use; verify final dose

Max dose1 mg initially; repeated glucagon may be ineffective and must not delay IV glucose

Severe insulin-associated hypoglycaemia when IV access is unavailable

Monitoring

Consciousness, glucose and nausea/vomiting; replenish carbohydrate once swallowing is safe

Contraindications: Reduced effectiveness with prolonged starvation, liver disease, depleted glycogen or repeated episodes

Escalation

Endocrinology co-management
NICU aware for LGA babies

⑮ Complications & their management

Shoulder dystocia

Emergency readiness at birth

Neonatal hypoglycaemia

Early feeding + checks

Future T2DM risk

Postpartum OGTT + annual screening + lifestyle programme

Post-treatment care

India programme: arrange a 75 g OGTT at 6 weeks postpartum and annual diabetes screening thereafter; a positive result needs referral and ongoing care.
NICE instead offers fasting plasma glucose at 6–13 weeks, with later fasting glucose/HbA1c options, and does not routinely offer a postpartum OGTT. Record the selected service pathway and ensure the test is actually reviewed.
Support breastfeeding, nutrition/activity, contraception and testing before a future pregnancy. Persistent hyperglycaemia after delivery needs assessment rather than automatic discharge from follow-up.

Diagnosis & assessment

Red flags:

Ketones + vomiting -> DKA/starvation ketosis
Macrosomia/polyhydramnios = control failure
Reduced movements late pregnancy
Steroid-course glucose spikes

Definition: Hyperglycaemia first detected in pregnancy needs classification, including assessment for pre-existing diabetes. The Indian programme uses a 75 g test irrespective of the last meal with a two-hour value ≥140 mg/dL; this is not a universal WHO or NICE diagnostic threshold.

Initial assessment

India NHM: test at first ANC; if an early test is negative, repeat at 24–28 weeks with at least 4 weeks between tests. If first seen after 28 weeks, test at that contact.
Record the actual test method, sample timing, units and diagnostic framework. A normal early result does not exclude later GDM.
At diagnosis assess HbA1c for possible pre-existing diabetes, symptoms/ketones when ill, glucose profile, medicines and maternal/fetal risks; arrange joint obstetric/diabetes review.
Use the antenatal guide for the India test preparation and timing. A positive result needs a documented nutrition, monitoring and treatment plan.

Investigations

Test	Looking for
Named diagnostic glucose test	Use the selected framework without combining fasting and non-fasting thresholds.
Self-monitored glucose log	Record fasting and post-meal timing, agreed treatment targets, hypoglycaemia and response to treatment.
Ketones / urgent metabolic assessment when ill	Vomiting, illness or hyperglycaemia can require urgent DKA assessment, even at a relatively modest glucose level.
Growth and amniotic fluid ultrasound	India 2018: 28–30 and 34–36 weeks, at least 3 weeks apart. NICE: every 4 weeks from 28 to 36 weeks. Use a documented service plan and bring forward assessment for concerns.

Algorithm

Entry pointGDM diagnosed: record framework and assess for pre-existing diabetes

NextNICE pathway: fasting glucose ≥7.0 mmol/L at diagnosis? ↓

DecisionNICE pathway: fasting glucose ≥7.0 mmol/L at diagnosis?

YESIndividualised insulin with nutrition/activity; ± metformin as appropriate ↓NONutrition/activity and glucose monitoring; consider immediate insulin at 6.0–6.9 with macrosomia/hydramnios ↓

ActionNutrition/activity and glucose monitoring; consider immediate insulin at 6.0–6.9 with macrosomia/hydramnios

NextTargets met within 1–2 weeks? ↓

DecisionTargets met within 1–2 weeks?

YESContinue glucose review, surveillance, birth and postpartum test planning ↓NOOffer metformin; insulin if unsuitable ↓

ActionOffer metformin; insulin if unsuitable

NextTargets met? ↓

DecisionTargets met?

YESContinue glucose review, surveillance, birth and postpartum test planning ↓NOIndividualised insulin with nutrition/activity; ± metformin as appropriate ↓

ActionIndividualised insulin with nutrition/activity; ± metformin as appropriate

NextContinue glucose review, surveillance, birth and postpartum test planning ↓

OutcomeContinue glucose review, surveillance, birth and postpartum test planning

Principles & follow-up

Management principles

Guideline conflict

India NHM GDM programme · 2018
Universal first-contact 75 g testing irrespective of the last meal; repeat an early negative result at 24–28 weeks, ≥4 weeks later. A two-hour value ≥140 mg/dL meets this programme’s criterion.

NICE NG3 · UK
Risk-based fasting 75 g OGTT; diagnosis if fasting ≥5.6 mmol/L OR two-hour ≥7.8 mmol/L. Previous GDM prompts early assessment and a 24–28-week repeat if normal.

Population/setting difference: Different screening services and test preparation; the shared 75 g load does not make the methods interchangeable.

Practical India consideration: Follow the named framework adopted by the maternity service and document the sample timing and units.

App default: For the India programme guide, use the national non-fasting method; show NICE separately when its pathway is used.
Reason: Prevents applying fasting diagnostic cutoffs to a non-fasting test or calling the Indian criterion a universal WHO threshold.

Guideline conflict

India NHM GDM programme · 2018
With good control, avoid routine birth before 39 weeks and schedule induction at or after 39 weeks if not already delivered; individualise earlier birth for complications.

NICE NG3 · UK
Uncomplicated GDM: give birth no later than 40+6 weeks. Consider earlier birth for maternal/fetal complications.

Population/setting difference: These describe different service timing policies, not a mandatory early-birth rule for every insulin-treated pregnancy.

Practical India consideration: Document the local senior obstetric plan using glucose control, growth and complications.

App default: Use the Indian service’s term induction plan with an explicit latest date; label the NICE 40+6 limit as the UK alternative.
Reason: Makes the actual birth plan explicit without imposing an unsourced 38-week delivery rule.

Guideline conflict

India NHM GDM programme · 2018
For medication-treated GDM, the labour pathway describes two-hourly glucose monitoring and glucose-based insulin adjustment.

NICE NG3 · UK
Hourly capillary glucose during labour/birth, target 4–7 mmol/L; IV insulin/dextrose if the target cannot be maintained.

Population/setting difference: Different monitoring and infusion protocols; rates cannot be transplanted between them without a complete prescription.

Practical India consideration: Agree the labour protocol and staffing before birth; escalate unstable glucose promptly.

App default: Display the hourly NICE target for close intrapartum monitoring, with an individually prescribed infusion if needed.
Reason: Frequent reassessment supports safe adjustment; a fixed insulin-to-glucose ratio is not a universal prescription.

Guideline conflict

India NHM GDM programme · 2018
Postpartum 75 g OGTT at 6 weeks, followed by annual screening if normal.

NICE NG3 · UK
Fasting plasma glucose at 6–13 weeks; later fasting glucose/HbA1c options, without routine postpartum OGTT. Continue annual testing.

Population/setting difference: The postpartum test offered differs; neither is a repeat pregnancy diagnostic test using pregnancy thresholds.

Practical India consideration: Give the actual test request, date and responsible reviewer before discharge.

App default: Use the six-week Indian OGTT follow-up when following the national programme; assess with non-pregnant diagnostic criteria.
Reason: Retains an actionable India-first follow-up while avoiding a hybrid NICE/India test instruction.

Sources (10)

MoHFW / National Health Mission — GDM: Technical and Operational Guidelines — 2018
· checked 2026-10-18 · verified-live
Open source ↗

Full primary PDF sections 4.4–4.6: universal first-contact testing, negative-test repeat at 24–28 weeks ≥4 weeks later, late presentation >28 weeks tested at first contact; 75 g glucose in ~300 mL within 5–10 min regardless of last meal, two-hour ≥140 mg/dL, plasma-calibrated method, vomiting within…

NICE — NG3 — diabetes in pregnancy
25 February 2015 · updated 16 December 2020 · checked 2026-10-18 · verified-live
Open source ↗

Scope: additional clinical-detail explanation for gdm, pregestational-diabetes. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Subsequent diagnos…

MSF — Metformin oral
· checked 2026-10-17 · verified-live
Open source ↗

Weekly 500 mg titration to 2 g/day, with meals, renal/acute-illness precautions; NICE NG3 separately provides pregnancy selection and targets.

MSF — Intermediate-acting insulin
· checked 2026-10-17 · verified-live
Open source ↗

Individualised once/twice-daily subcutaneous dosing, U-100 matching devices, NEVER-IV instruction and compatible insulin mixing order; no universal GDM starting dose invented.

JBDS-IP / ABCD / Diabetes UK — Hospital Management of Hypoglycaemia in Adults — January 2023
· checked 2026-10-18 · verified-live
Open source ↗

Treat <4 mmol/L, oral carbohydrate if safe, IV glucose 20 g using 10%/20% solutions, IM glucagon 1 mg, repeat glucose checks and subsequent carbohydrate/insulin review. Additional admission/discharge check 18 October 2026 (limited to the following): Education, precipitating-cause review, ongoing glu…

NICE — Postnatal care — NG194
· checked 2026-10-18 · verified-live
Open source ↗

Maternal/newborn transfer assessment, first void and effective feeding, handover, support/safeguarding, first midwife visit within 36 hours after transfer, postnatal danger symptoms. Full recommendations page read.

India MoHFW / NHM — District Hospital Standard Operating Procedures — LaQshya
· checked 2026-10-18 · verified-live
Open source ↗

Normal-delivery discharge not less than 48 hours: full primary SOP PDF normal-delivery/discharge passages read. Corroborated by NHM CEmONC 2024 Part 1, chapter 8. This does not define a universal post-caesarean or complicated-case stay.

WHO — WHO recommendations on quality postnatal care — official recommendation summary
· checked 2026-10-18 · verified-live
Open source ↗

Official WHO summary read: at least 24-hour facility care after birth; additional contacts at 48–72 hours, 7–14 days and week 6; individual assessment/support. Summary facts only, not a claim that the full 242-page PDF was reviewed.

RCOG — Laparoscopy — recovering well
· checked 2026-10-18 · verified-live
Open source ↗

Full primary patient recovery page read: pain control, wounds, activity/VTE, urinary/bowel and infection warning signs, adult support and no driving/important decisions during the first 24 hours after general anaesthesia. Used as general recovery/handover principles, not operation-specific discharge…

NICE — Acutely ill adults in hospital — CG50
· checked 2026-10-18 · verified-live
Open source ↗

Full primary recommendations read, focusing on critical-care-to-ward transfer: structured written handover, shared plan, monitoring, rehabilitation and receiving-team capability. Step-down is distinct from home discharge; no universal organ-support discharge cutoff is asserted.